

Special Issue

Precision Oncology: Targeting Molecular Subtypes in Cancer Therapy

Message from the Guest Editors

This Special Issue, entitled "Precision Oncology: Targeting Molecular Subtypes in Cancer Therapy", aims to explore current challenges and future directions in molecular subtyping for cancer treatment. We seek to highlight innovative approaches for identifying and targeting specific molecular subtypes, overcoming resistance mechanisms, and implementing precision diagnostics in clinical practice. Recent technological advances in genomic profiling, liquid biopsies, and artificial intelligence have dramatically enhanced our ability to identify actionable molecular alterations and monitor treatment response in real time. These developments create unprecedented opportunities for refining treatment selection and developing novel therapeutic strategies for molecularly defined patient subgroups. We invite the submission of original research articles and comprehensive reviews addressing molecular subtyping methodologies, biomarker discovery, resistance mechanisms, multi-omics integration, emerging diagnostic technologies, and innovative clinical trial designs for molecular subtypes in oncology.

Guest Editors

Dr. Shuhei Suzuki

1. Department of Internal Medicine (Clinical Oncology), Yamagata Prefectural Shinjo Hospital, 720-1 Kanazawa, Shinjo 996-8585, Japan
2. Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan
3. Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
4. Department of Molecular Cancer Science, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan

Dr. Jiro Ogura

Department of Pharmacology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan

Deadline for manuscript submissions

30 October 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/235361

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)